Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials

BACKGROUND: NVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series demonstrated efficacy rates of 89.7–90.4 % and an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Katherine, Hegazy, Karim, Cai, Miranda R., McKnight, Irene, Rousculp, Matthew D., Alves, Katia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169578/
https://www.ncbi.nlm.nih.gov/pubmed/37211453
http://dx.doi.org/10.1016/j.vaccine.2023.05.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169578/
https://www.ncbi.nlm.nih.gov/pubmed/37211453
http://dx.doi.org/10.1016/j.vaccine.2023.05.016

Ejemplares similares